Early post-bevacizumab change in rCBV from DSC-MRI identifies pseudoresponse in recurrent glioblastoma: Results from ACRIN 6677/RTOG 0625

BackgroundProgressive enhancement predicted poor survival in ACRIN 6677/RTOG 0625, a multi-center trial of bevacizumab with irinotecan or temozolomide in recurrent glioblastoma, but pseudoresponse likely limited enhancement-based survival prognostication in T1 non-progressors. We aimed to determine...

Descripció completa

Dades bibliogràfiques

Autors principals:	Jerrold L. Boxerman, Bradley S. Snyder, Daniel P. Barboriak, Kathleen M. Schmainda
Format:	Artigo
Idioma:	Inglês
Publicat:	Frontiers Media S.A. 2023-01-01
Col·lecció:	Frontiers in Oncology
Matèries:	recurrent glioblastoma bevacizumab pseudoresponse DSC-MRI (CBV) cerebral blood volume
Accés en línia:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1061502/full
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!